A statement of changes in beneficial ownership was filed on August 18, 2026, disclosing that Brent Pfeiffenberger, President and CEO of Century Therapeutics, Inc., had 31,172 shares of common stock withheld by the issuer on August 14, 2026, to satisfy tax withholding obligations connected to the vesting of restricted stock units.

Key Highlights

  • Reporting person: Brent Pfeiffenberger, President and CEO, and a Director of Century Therapeutics, Inc. (NASDAQ:IPSC)
  • Transaction date: August 14, 2026, with the filing submitted on August 18, 2026
  • Shares withheld: 31,172 shares of common stock disposed of (transaction code F) at a price of $1.92 per share
  • Purpose of transaction: Shares were withheld by the issuer to satisfy tax withholding obligations upon vesting of restricted stock units, according to the filing
  • Resulting ownership: Pfeiffenberger directly holds 3,634,302 shares of common stock following the reported transaction
  • Filing type: The form was filed by one reporting person, with Douglas Carr signing as Attorney-in-Fact

RSU Vesting and Tax Withholding at Century Therapeutics

According to the filing, the transaction recorded under transaction code "F" reflects shares withheld by Century Therapeutics, Inc., a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker IPSC, to cover tax obligations arising from the vesting of restricted stock units held by its President and CEO. This type of withholding is a standard mechanism companies use to fulfill an employee's tax liability at the point of RSU vesting, rather than requiring the individual to sell shares on the open market.

The filing indicates that 31,172 shares were disposed of at a price of $1.92 per share on August 14, 2026. Following this transaction, Pfeiffenberger's direct beneficial ownership in Century Therapeutics common stock stands at 3,634,302 shares. No derivative securities transactions were reported in Table II of the filing, and no indirect ownership positions were listed. The form was filed individually, not as part of a joint or group filing, and was signed by Douglas Carr as Attorney-in-Fact on August 18, 2026.

What Was Disclosed

The filing disclosed a single disposition of 31,172 shares of Century Therapeutics common stock at $1.92 per share by President and CEO Brent Pfeiffenberger on August 14, 2026, representing shares withheld by the company to satisfy RSU vesting-related tax obligations, leaving him with 3,634,302 shares held directly.